Swiss biotech raises $50.6M to further hearing-loss drugs

Emily Mullin Swiss biotech Auris Medical has raised $ 50.6 million in a Series C round of financing to advance its two major therapeutics for the treatment of inner ear disorders. The ...

Elderly in South often prescribed drugs with dangerous side effects

Eric Palmer Drugmakers have sometimes been accused of marketing drugs for the elderly that might not be in their best interest. But a new study says doctors in the Southern part of ...

CEO Chris Viehbacher steers Sanofi clear of drugs for Alzheimer’s disease

Eric Palmer Any company that can develop a drug even partially effective against Alzheimer's disease will strike a gold mine. One analyst estimates the opportunity to be $ 20 ...

Which drugs are the biggest duds in blockbuster-land?

Tracy Staton Now that March Madness is over, and everyone knows how they fared in the office pool, we have another tournament story for you. Call it blockbuster bedlam. EvaluatePharma ...

Biotech Chimerix shines in IPO debut as interest grows in antiviral drugs

Ryan McBride Chimerix sped out of the IPO gate on Thursday. The Durham, NC-based drug developer's ($ CMRX) stock soared on its first day of trading, with an initial price of $ ...

Sanofi at vanguard with new process for antimalarial drugs

Eric Palmer French drugmaker Sanofi ($ SNY) said today it is gearing up to produce tons of artemisinin, the key ingredient for antimalarial treatments. Artemisinin usually comes ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS